JP2008535907A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535907A5
JP2008535907A5 JP2008505998A JP2008505998A JP2008535907A5 JP 2008535907 A5 JP2008535907 A5 JP 2008535907A5 JP 2008505998 A JP2008505998 A JP 2008505998A JP 2008505998 A JP2008505998 A JP 2008505998A JP 2008535907 A5 JP2008535907 A5 JP 2008535907A5
Authority
JP
Japan
Prior art keywords
average
active agent
formulation
max
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535907A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/003865 external-priority patent/WO2007069073A2/en
Publication of JP2008535907A publication Critical patent/JP2008535907A/ja
Publication of JP2008535907A5 publication Critical patent/JP2008535907A5/ja
Pending legal-status Critical Current

Links

JP2008505998A 2005-04-12 2006-04-12 アミロイド阻害化合物の薬学的製剤 Pending JP2008535907A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67022405P 2005-04-12 2005-04-12
PCT/IB2006/003865 WO2007069073A2 (en) 2005-04-12 2006-04-12 Pharmaceutical formulations of amyloid inhibiting compounds

Publications (2)

Publication Number Publication Date
JP2008535907A JP2008535907A (ja) 2008-09-04
JP2008535907A5 true JP2008535907A5 (enExample) 2009-05-21

Family

ID=38163292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505998A Pending JP2008535907A (ja) 2005-04-12 2006-04-12 アミロイド阻害化合物の薬学的製剤

Country Status (8)

Country Link
US (2) US20060257480A1 (enExample)
EP (1) EP1890685A2 (enExample)
JP (1) JP2008535907A (enExample)
KR (1) KR20070120190A (enExample)
CN (1) CN101193628A (enExample)
CA (1) CA2611586A1 (enExample)
WO (1) WO2007069073A2 (enExample)
ZA (1) ZA200708699B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049638A1 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
CA2830727C (en) 2006-10-12 2016-11-29 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2010096925A1 (en) * 2009-02-26 2010-09-02 Bellus Health (International) Limited Homotaurine-supplemented and/or enriched edible material, methods of preparation an d uses
CN103875786A (zh) * 2014-02-27 2014-06-25 如皋市坝新肠衣有限公司 一种肠衣的生产工艺
SMT202300250T1 (it) * 2015-09-10 2023-09-06 Alzheon Inc Trattamento della malattia di alzheimer in una particolare popolazione di pazienti
EP4103604A4 (en) * 2020-02-13 2024-03-27 Cognition Therapeutics, Inc. Method of decreasing amyloid beta monomer levels in patients with cognitive decline
US12336972B2 (en) * 2021-01-22 2025-06-24 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for treating neurocognitive disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
ATE357221T1 (de) * 1994-04-22 2007-04-15 Astellas Pharma Inc Kolon-spezifisches arzneistofffreisetzungssystem
CA2229427A1 (en) * 1995-09-12 1997-03-20 The General Hospital Corporation Method for early detection of ovarian cancer
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
KR20090016517A (ko) * 1999-12-23 2009-02-13 벨루스 헬스 (인터내셔널) 리미티드 대뇌 아밀로이드 혈관병증을 조절하는 화합물 및 방법
FR2832928B1 (fr) * 2001-11-30 2004-02-06 Dermo Cosmologie Lab De Composition a base d'ester de diosgenine applicable par voie topique
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders

Similar Documents

Publication Publication Date Title
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
JP7502197B2 (ja) セピアプテリン血漿曝露を増加させるための方法
CN100577171C (zh) 治疗重度心力衰竭的药物
JP2009513713A5 (enExample)
WO2018193648A1 (ja) アルカリ性化剤による血液浄化
JP2024544572A (ja) Rock2阻害剤のナノ結晶製剤およびその調製方法
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
CN120091814A (zh) 用slc6a19功能的哌啶抑制剂治疗pku的给药方案
JP5680412B2 (ja) レオヌリンの使用およびその組成物
CN101257898A (zh) 艾司佐匹克隆与o-去甲基文拉法辛的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
JP2008535907A5 (enExample)
JP2009526834A5 (enExample)
JPWO2019232130A5 (enExample)
HU229214B1 (hu) Propionil-L-karnitint és további hatóanyagokat tartalmazó kombinációs készítmény alkalmazása merevedési zavar kezelésére
RU2391095C1 (ru) Фармацевтическая композиция, включающая холина альфосцерат и гопантеновую кислоту (или ее соль), для лечения недостаточности кровообращения мозга и эректильной дисфункции
WO1996004917A1 (en) Remedy for myotonic dystrophy
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および/または近視進行抑制剤
JP5576006B2 (ja) 1日2回服用型経口投与製剤
JP2013047257A (ja) ヒトの血小板レベルを増加させるための組成物および方法
JP5376785B2 (ja) 医薬組成物
JP6420923B1 (ja) 医薬
JP2010013364A (ja) 高尿酸血症の予防または改善剤
JP6188784B2 (ja) 炎症性および免疫性疾患の治療のための組成物
US11858908B2 (en) Compositions and methods for inhibiting IDO1
JP5962161B2 (ja) 耳管開放症治療剤